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Background: It is important to evaluate patients with transient ischemic attack (TIA) or
stroke for atrial fibrillation (AF) because the detection of AF changes the recommended
anti-thrombotic regimen from treatment with an antiplatelet agent to oral anticoagulation.
This study describes the diagnostic yield of a patch-based, single-use, and water-resistant
14-day continuous cardiac rhythm monitor (ZIO Patch) in patients with stroke or TIA.
Methods:We obtained data from the manufacturer and servicer of the ZIO Patch (iRhythm
Technologies). Patients who were monitored between January 2012 and June 2013 and
whose indication for monitoring was TIA or stroke were included. The duration of mon-
itoring, the number and type of arrhythmias, and the time to first arrhythmia were
documented.
Results: One thousand one hundred seventy-one monitoring reports were analyzed. The
mean monitor wear time was 10.9 days and the median wear time was 13.0 days (interquar-
tile range 7.2–14.0). The median analyzable time relative to the total wear time was 98.7%
(IQR 96.0–99.5%). AF was present in 5.0% of all reports. The mean duration before the
first episode of paroxysmal AF (PAF) was 1.5 days and the median duration was 0.4 days.
14.3% of first PAF episodes occurred after 48 h. The mean PAF burden was 12.7% of the
total monitoring duration.
Conclusion: Excellent quality of the recordings and very good patient compliance coupled
with a substantial proportion of AF detection beyond the first 48 h of monitoring suggest
that the cardiac patch is superior to conventional 48-h Holter monitors for AF detection in
patients with stroke or TIA.
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INTRODUCTION
It is important to evaluate patients with stroke or transient
ischemic attack (TIA) for atrial fibrillation (AF), because the detec-
tion of AF changes the recommended anti-thrombotic regimen
from treatment with an antiplatelet agent to treatment with oral
anticoagulation (1).
Atrial fibrillation is a well-recognized cause of stroke and TIA
and recent studies of extended cardiac rhythm monitoring demon-
strate that AF may be responsible for a greater proportion of unex-
plained strokes than previously realized. In a systematic review
and meta-analysis of 32 studies of patients with stroke or TIA, the
overall detection rate of AF was 11.5% (2). In the recent CRYSTAL-
AF study, AF was detected in 29% of cryptogenic stroke patients
who underwent 1 year of cardiac monitoring with an implantable
cardiac loop recorder (3). The detection of supraventricular tachy-
cardia (SVT) may be important as well as it is associated with the
development of AF and an increased risk of stroke even in patients
without AF (4–6). These results suggest an important role for
extended cardiac monitoring in the evaluation of patients with
stroke or TIA.
Because of memory and technical limitations, ambulatory car-
diac monitoring has historically provided either short-term (up to
48 h) continuous monitoring (Holter) or longer term intermittent
monitoring (event or loop recorders). Longer term continuous
monitoring has been limited by patient compliance, the analyzable
wear time, and electrode skin irritation (7). A novel, patch-based,
water-resistant cardiac patch rhythm monitor (ZIO Patch) can
provide continuous cardiac monitoring for up to 14 days. A recent
study in patients with cardiac indications concluded that the patch
monitor has high patient compliance, high analyzable time, and
incremental diagnostic yield beyond 48 h for all arrhythmia types
(8). We investigated the diagnostic yield of the cardiac patch
monitor for long-term continuous cardiac monitoring in a large
nationwide sample of stroke and TIA patients.
MATERIALS AND METHODS
The self-adhesive cardiac patch was typically applied by trained
technicians at the ordering clinic or hospital. A button could
be pressed on the patch by the patient to annotate symptoms
[Figure 1, Ref. (8)]. During the monitoring period the patient
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FIGURE 1 | Ziopatch cardiac monitor. Zio Patch button and placement.
(A) Patients can press a button on the Zio Patch to mark a symptomatic
episode. (B) The device is placed over the patient’s left pectoral region.
(Images courtesy of iRhythm Technologies, Inc., San Francisco, CA, USA.)
kept a diary of symptoms and annotations. After completion of
the monitoring period, the patient mailed the device and diary
to a central data processing center, where the data were ana-
lyzed by proprietary computer algorithms in conjunction with
certified cardiac technicians and cardiologists to curate a clinical
report.
All patients who underwent monitoring with the ZIO Service in
the United States between January 2012 and June 2013 and whose
indication for monitoring, entered as free text by the ordering
provider, was stroke or TIA were included in this study.
We obtained the de-identified monitoring data from the data
processing center (iRhythm Technologies Inc., San Francisco, CA,
USA). This research was exempt from IRB review and approval as
it did not meet criteria for human subjects research. All data were
collected as part of routine clinical practice and the investigators
could not ascertain the identity of the individual patients included
in the study. The data were transferred after removal of all patient-,
physician-, and site-level identifiers. The duration of monitoring,
analyzable signal time, the number and type of arrhythmias, and
the time to first arrhythmia were documented. The duration of
monitoring was calculated as the total wear time, which was from
the point of activation to the point of the last recorded analyz-
able signal. Analyzable signal time was defined as the proportion
of the total wear time that the electrocardiographic (ECG) sig-
nal is interpretable (sufficiently free of noise). SVT was defined as
four or more supraventricular ectopic beats and AF was defined
as R–R irregularity for more than 30 s. AF was classified as either
paroxysmal or chronic (100% of analyzable time). For patients
with paroxysmal AF (PAF), the AF burden was calculated as the
proportion of the analyzable signal time that consisted of AF. The
cumulative diagnostic yield was calculated based on the method
of Kaplan and Meier.
RESULTS
One thousand one hundred seventy-one monitoring reports
were analyzed. The average patient age was 67.9 years and 55%
of patients were men. The median wear time was 13.0 days
[interquartile range (IQR) 7.2–14.0]. 97.1% of the patients wore
the monitor for more than 48 h, 91.9% wore the monitor for more
than 4 days, and 66.9% wore the monitor for more than 10 days.
The mean analyzable time, expressed as a proportion of the total
wear time, was 95.8%. The median analyzable time was 98.7%
(IQR 96.0–99.5%).
Using Kaplan–Meier statistics, the frequency of AF at 14 days
was 5.0% (4.4% PAF and 0.6% chronic AF) (Figure 2). The mean
duration before the first episode of PAF was 1.5 days and the
median duration before the first episode was 0.4 days. 14.3% of
first PAF episodes occurred after 48 h. The mean PAF burden was
12.7% of the total monitoring duration. The median PAF burden
in hours was 0.33 h (IQR 0.11–1.33).
Supraventricular tachycardia of four beats or more was present
in 70.2% of recordings. SVT of eight beats or more was present
in 51% of recordings. ninety-nine percent of patients with SVT
had no AF. The mean duration before the first SVT recording was
2.1 days. The median duration of the longest SVT recording was
5.9 s (IQR 3.3–10.6). The median number of beats in the longest
SVT recording was 12 (IQR 7–22).
DISCUSSION
This is the first large-scale study of cardiac patch monitoring in
patients with a history of stroke or TIA. It demonstrates that the
cardiac patch, a novel device for detection of AF and other cardiac
arrhythmias, is well tolerated and results in detection of AF in 5%
of patients with stroke or TIA. A substantial proportion of patients
with PAF had their first episode more than 48 h after the start of
the monitoring period. These findings indicate that extended con-
tinuous monitoring with the cardiac patch monitor may lead to
the identification of AF that would likely have been missed with
traditional 48-h Holter monitoring.
The very high rate of SVT detection (70%) in this patient pop-
ulation with a history of stroke or TIA is noteworthy. However, the
median duration of SVT was very short (6 s) and the significance
of short episodes of SVT is unclear. A recent study of patients with
pacemakers or implantable cardioverter-defibrillators showed that
subclinical atrial tachyarrhythmia, a form of SVT, defined as an
episode of rapid atrial rate (≥190 beats per minute) lasting more
than 6 min, often preceded the development of clinical AF. It also
showed a nearly 2.5-fold increased risk of stroke in patients with
atrial tachyarrhythmias, regardless of the presence of AF (9). Fur-
ther studies are needed to elucidate the association between short
runs of SVT and stroke and to determine if anticoagulation is
superior to antiplatelet therapy for secondary stroke prevention in
certain patients with SVT (e.g., presence of long and/or frequent
episodes). It should be stressed that detection of SVT is currently
not an indication for oral anticoagulation in patients with a history
of stroke or TIA.
Patch monitoring had very high patient compliance (median
wear time 13.0 days) and analyzable time (98.7%). This might have
resulted from the practical benefits of patch-based monitoring
compared with traditional “Holter” monitors that have detach-
able leads, removable skin electrodes, and a separate recording
unit. These benefits include its small size, its water resistance, and
the absence of wired skin electrodes. Difficulty of use, skin infec-
tion or irritation, and disruption to the patient’s work, travel, and
lifestyle have been reported as causes of reduced compliance in
previous studies with lead-based extended monitors (7, 10). Wired
monitors are also limited by motion artifact during exercise and
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FIGURE 2 | Cumulative frequency of atrial fibrillation. Shown is the probability of detection of atrial fibrillation in stroke and TIA patients with cardiac patch
monitoring up to 14 days. The data are shown on an enlarged y -axis.
other physical activity and must be removed before showering and
contact with water.
There were several differences between our study and prior
studies of cardiac monitoring. In contrast to prior post-stroke or
TIA studies, which typically obtained detailed data on a relatively
small number of patients, our study included a national sample
of all stroke and TIA patients who underwent cardiac patch mon-
itoring in the US during an 18-month time-period. Due to the
retrospective design, however, we had limited clinical data on the
subjects in the study. For example, we had no data on the presumed
etiology of the strokes and TIAs.
Another limitation is confounding by indication. The clinical
indication of stroke or TIA was based on free-text input from the
ordering provider. It could be that clinicians preferentially ordered
cardiac patch monitoring, as opposed to shorter term monitoring,
when they suspected a low likelihood of arrhythmias. This could
underestimate the true AF yield with cardiac patch monitoring in
all-comers with stroke or TIA. Alternatively, if physicians prefer-
entially ordered cardiac patch monitoring when they suspected a
high likelihood of AF, the results could be an overestimation of the
AF detection rate in all-comers.
The rate of AF detection in this study (5%) was lower than
in most previous studies of cardiac monitoring in stroke and
TIA patients. This may, in part, be explained by differences in
the proportions of patients with cryptogenic strokes. The cur-
rent study likely consisted of a more heterogeneous stroke and
TIA population, including many patients with non-cryptogenic
strokes, whereas most prior studies have preferentially enrolled
patients with cryptogenic strokes. A meta-analysis of cardiac mon-
itoring in patients with stroke or TIA has shown that the rate
of AF detection is significantly higher in patients with cryp-
togenic strokes (15%) than in patients with non-cryptogenic
strokes (11.5%) (2). In EMBRACE, a recent large multicenter
randomized study of patients with cryptogenic stroke or TIA,
AF was detected in 16% of patients after 30 days of cardiac
monitoring (11).
Variation in monitoring duration may also have contributed to
differences in the detection rate of AF. In our study, we found the
highest rate of AF detection in the first days of monitoring and
a marked decline in the yield of AF detection during the second
week. These results suggest that a 2-week monitoring duration
may be sufficiently long. However, the optimal duration of mon-
itoring is not known and longer monitoring will likely increase
the yield of AF detection. This is exemplified by the results of
the CRYSTAL-AF study, which assessed the diagnostic yield of an
implantable cardiac loop recorder during 3 years of monitoring. In
this study, the yield of AF detection at 6, 12, and 36 months was 8.9,
12.4, and 30% (3). The increased yield of AF detection with multi-
year cardiac monitoring should be weighed against the drawbacks
associated with the use of an implantable cardiac loop recorder,
including the need for an invasive procedure, cost, incompatibility
with magnetic resonance imaging, and procedural risks such as
infection.
Another limitation of our study is the lack of a direct com-
parison group. It is possible that a subset of the patients would
have been diagnosed with AF even if they had no patch monitor,
either during routine clinical follow-up or because they experi-
enced symptoms from their PAF. A proposed study, comparing
AF detection rates among stroke and TIA patients randomized to
the cardiac patch monitor versus a traditional Holter monitor, will
address this issue.
In sum, our data indicate that AF detection in stroke patients
with a 14-day cardiac patch monitor is associated with excellent
recording quality, high patient compliance, and a substantial pro-
portion of AF detection that occurs beyond the first 48 h of record-
ing. This suggests that cardiac patch monitoring will increase
the detection of AF in stroke and TIA patients as compared to
traditional 48-h Holter monitoring.
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